OCUP News and Press, Ocuphire Pharma Inc Com From 01/20/21

Durability of Nyxol’s Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD Ocuphire Invited to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase on Jan...

Clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma ([[OCUP]] -1.5%) has completed enrollment in its MIRA-2 Phase 3 study evaluating the safety and efficacy of Nyxol to reverse pharmacologically-induced mydriasis ((dilation of the pupil of the eye)).Nyxol i...

Nyxol has Potential to be a New Treatment Option for Reversal of Pharmacologically-Induced Pupil Dilation Top-Line Data for MIRA-2 Expected by End of Q1 2021 FARMINGTON HILLS, Mich., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage oph...

Ocuphire Pharma (OCUP) has initiated patient recruitment and screening in late December for its LYNX-1 Phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances ((NVD)) in U.S. Patients with NVD experience glare, halos, starbursts and decreased c...

Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication Top Line Data from LYNX-1 Expected 3Q2021 FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focu...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, President and Chief Execut...

FARMINGTON HILLS, Mich., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, Chief Executive Officer, C...

Begins Enrollment in the First of Four Upcoming Late-Stage Trials in the U.S. Announces MIRA-1 Phase 2b Study Accepted for Peer-Reviewed Publication in Optometry and Vision Science FARMINGTON HILLS, Mich., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., (Nasdaq:...

Allow ed Japanese Patent Application for Daily Ophthalmic Use of Nyxol to Improve Visual Performance R&D Funding for APX3330 and Pipeline Candidates with $1.7M NIH National Eye Institute Grant FARMINGTON HILLS, Mich.,...